BeiGene Launches Proposed Public Offering by Selling Shareholders Cambridge, Mass. and Beijing, China

BeiGene Launches Proposed Public Offering

by Selling Shareholders

Cambridge, Mass. and Beijing, China,

December 1, 2020 - BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused

on developing and commercializing innovative medicines worldwide, today announced the commencement of an underwritten public offering

of 1,511,546 American Depositary Shares ("ADSs"), each representing 13 of its ordinary shares, par value $0.0001 per

share, by fund partnerships affiliated with Baker Bros. Advisors LP (the "Selling Shareholders"). The Selling Shareholders

also intend to grant the underwriter a 30-day option to purchase up to an additional 151,154 ADSs. BeiGene will not receive any

of the proceeds from the sale of the shares being offered by the Selling Shareholders but will bear certain expenses incident to

this offering (excluding underwriting discounts and commissions).

Goldman Sachs & Co. LLC is acting

as the underwriter for the offering. The offering is subject to market and other conditions, and there can be no assurance as to

whether or when the offering may be completed or as to the actual size or terms of the offering.

An automatically effective shelf registration

statement on Form S-3 was filed with the Securities and Exchange Commission ("SEC") on May 11, 2020. The

proposed offering will be made only by means of a prospectus and prospectus supplement. A copy of the preliminary prospectus supplement

relating to this offering may be obtained, when available, by visiting the SEC's website at www.sec.gov or by contacting

the offices of Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone:

1-866-471-2526 or by emailing prospectus-ny@ny.email.gs.com. The final terms of the offering will be disclosed in a final prospectus

supplement to be filed with the SEC.

This press release shall not constitute

an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities

in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification

under the securities laws of any such state or jurisdiction.

BeiGene is a global, commercial-stage biotechnology

company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes

and access for patients worldwide. Our 4,700+ employees in China, the United States, Australia, Europe, and elsewhere are committed

to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology

products: BTK inhibitor BRUKINSA (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China.

We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics S rl,

a Bristol Myers Squibb (BMS) company, and EUSA Pharma.

Note Regarding Forward-Looking

This press release contains

forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including BeiGene's

current intentions, expectations or beliefs regarding the offering of ADSs representing ordinary shares, including its expectations

regarding the completion, size or terms of the offering, and BeiGene's plan to market additional oncology products in China.

These statements may be preceded by, followed by or include the words "aim," "anticipate," "believe,"

"estimate," "expect," "forecast," "intend," "likely," "outlook," "plan,"

"potential," "project," "projection," "seek," "can," "could," "may,"

"should," "would," "will," the negatives thereof and other words and terms of similar meaning. Forward-looking

statements include all statements that are not historical facts. Such forward-looking statements are subject to various risks and

uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially

from those indicated in these statements. There is no assurance that any forward-looking statements will materialize. You are cautioned

not to place undue reliance on forward-looking statements, which reflect expectations only as of this date. BeiGene does not undertake

any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments,